Axogen Inc vs W W Grainger Inc — how do they compare? Axogen Inc trades at $39.4 (market cap $2.06B), while W W Grainger Inc trades at $1,365.59 (market cap $64.73B). The key difference: W W Grainger Inc is far larger — about 31.4× Axogen Inc's market cap, and W W Grainger Inc pays a 0.68% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | GWW | |
|---|---|---|
Market Cap | $2.06B | $64.73B |
Sector | Technology | Technology |
52-Week High | $46.19 | $1.39K |
52-Week Low | $11.28 | $918.18 |
Enterprise Value | $1.98B | $66.82B |
Dividend Yield | — | 0.68% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
GWW trades at $1,391.68, up 1.16% today, with a bullish technical outlook supported by moving averages and strong momentum. The company reported Q1 2026 EPS of $11.65, beating estimates, and raised its full-year guidance. Revenue growth remains steady, with 2026 revenue projected at $18.4B, while profitability metrics like ROE of 48.1% and net margin near 10% highlight operational strength. Positive analyst sentiment and recent dividend declarations reinforce investor confidence amid a favorable market backdrop.
The outlook for GWW is positive, driven by earnings beats and raised guidance, though valuation multiples like a P/E of 36.87 suggest premium pricing. Risks include economic sensitivity and competitive pressures, but institutional buy ratings and technical support near $1,380 provide a cushion for upward momentum if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →